PENTAX has identified therapeutic endoscopy devices as a priority for its new investment. Creo will be able to expand PENTAX’s footprint in the therapeutics market.
“We welcome new investor, PENTAX Medical, who has identified endoscopic therapeutic devices as a priority area, and supports our vision to be leaders in electrosurgery. With this investment we are well positioned to complete U.S. regulatory approval, build on our growing intellectual property portfolio and develop commercial traction in key global markets,” said Creo CEO Craig Gulliford.
More articles on gastroenterology:
Dr. Ashley Canipe joins Indian River Medical Center
IBD market to grow at 3.95% until 2019: 5 trends to note
3 recent transactions in the GI field
